Brain Tumor Pathology

Papers
(The TQCC of Brain Tumor Pathology is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Clinical, histopathological and molecular risk factors for recurrence of pilocytic astrocytomas: brainstem/spinal location, nestin expression and gain of 7q and 19 are associated with early tumor recu44
Preface for Brain Tumor Pathology vol.41 issue 221
IDH wild-type lower-grade gliomas with glioblastoma molecular features: a systematic review and meta-analysis18
Correlation of MTAP immunohistochemical deficiency with CDKN2A homozygous deletion and clinicopathological features in pleomorphic xanthoastrocytoma14
Droplet digital PCR assay for detecting TERT promoter mutations in patients with glioma14
Central nervous system ALK-negative anaplastic large cell lymphoma with IRF4/DUSP22 rearrangement13
The oligodendroglial histological features are not independently predictive of patient prognosis in lower-grade gliomas13
Double-hit primary central nervous system lymphoma with histogenetically proven bone marrow infiltration: a case report and a review of the literature13
Beyond the WHO 2021 classification of the tumors of the central nervous system: transitioning from the 5th edition to the next12
FISH analysis reveals CDKN2A and IFNA14 co-deletion is heterogeneous and is a prominent feature of glioblastoma11
A clinicopathological analysis of supratentorial ependymoma, ZFTA fusion-positive: utility of immunohistochemical detection of CDKN2A alterations and characteristics of the immune microenvironment11
Primary central nervous system lymphoma: clinicopathological and genomic insights for therapeutic development11
Histopathological predictors of progression-free survival in atypical meningioma: a single-center retrospective cohort and meta-analysis11
Anti-angiogenic and macrophage-based therapeutic strategies for glioma immunotherapy10
Correction: Beyond the WHO 2021 classification of the tumors of the central nervous system: transitioning from the 5th edition to the next10
Lynch syndrome-associated chordoma with high tumor mutational burden and significant response to immune checkpoint inhibitors10
Predicting BRAF V600E mutation in glioblastoma: utility of radiographic features10
Pediatric diffuse glioma with EP300::BCOR fusion manifesting as low-grade epilepsy-associated neuroepithelial tumor: a case presentation8
Comparative analyses of immune cells and alpha-smooth muscle actin-positive cells under the immunological microenvironment between with and without dense fibrosis in primary central nervous system lym8
Revisiting vimentin: a negative surrogate marker of molecularly defined oligodendroglioma in adult type diffuse glioma7
Tectal glioma: clinical, radiological, and pathological features, and the importance of molecular analysis7
Three-dimensional visualization of human brain tumors using the CUBIC technique7
The 2021 WHO classification of tumors, 5th edition, central nervous system tumors: the 10 basic principles7
Preface for Brain Tumor Pathology vol. 39 issue 27
Easy-to-use machine learning system for the prediction of IDH mutation and 1p/19q codeletion using MRI images of adult-type diffuse gliomas6
Timing of H3K27me3 loss in secondary anaplastic meningiomas6
Spontaneous malignant transformation of trigeminal schwannoma: consideration of responsible gene alterations for tumorigenesis—a case report6
Revisiting the definition of glioma recurrence based on a phylogenetic investigation of primary and re-emerging tumor samples: a case report6
0.031789064407349